Peregrine's Antibody Found Effective Against Tumor Growth
Posted on: Thursday, 15 November 2007, 06:00 CST
Peregrine Pharmaceuticals has reported that preclinical data showed anti-VEGF antibody R84 as effective was as Avastin in inhibiting tumor growth in a mouse model of human breast cancer.
R84 is a selective, fully human monoclonal antibody that blocks the cancer-promoting agent vascular endothelial growth factor.
The study results showed that tumor-associated macrophages are reduced after R84 therapy. In addition, the data showed that when given for a prolonged period, R84 decreased microvessel density and expression of VEGFR2, demonstrating that the antibody is acting to reduce VEGF-induced angiogenesis in tumor tissue.
Treatment with R84 reduced the growth of well-established breast tumors by 55%, equivalent to the reduction achieved with Avastin. The researchers also demonstrated that R84 and Avastin were equally effective at controlling tumor growth in a preclinical model of sarcoma. In every preclinical tumor model evaluated thus far, the anti-tumor activity of R84 has been comparable to that of Avastin.
Peregrine in association with Affitech has filed a patent application for R84 with the US Patent and Trademark Office to preserve the right to obtain patent protection in the US, EU and the rest of the world.
Steven King, president and CEO of Peregrine, said: "We are delighted that R84 is generating similar, and potentially superior, results in preclinical cancer models. As a result of these positive developments, we are initiating additional preclinical studies to advance R84 as our next potential clinical candidate."
Source: Datamonitor
Related Articles
- Researchers Identify Role Of Gene In Tumor Development, Growth And Progression
- Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
- Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
- Marijuana May Inhibit Tumor Cell Growth
- Preclinical Data Show Alfacell's ONCONASE(R) Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
- Doctors Remove Teen's Tumor-Like Growth
- FibroGen Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer
- Setting the Benchmark in Brain Tumor Treatment at The University of Texas M. D. Anderson Cancer Center
- Omega-6 Fatty Acids Cause Prostate Tumor Cell Growth in Culture
- Induction of Anti-Tumor Immune Response in Murine Models
 |
 |
User Comments (0)
RSS Feeds